Rituxan for focal gelomelural sclerosis and minimal change disease – pro
Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are types of glomerulonephritis. MCD is an immune-mediated condition affecting the kidneys, FSGS is not a specific disease entity but a histological lesion, often of unknown aetiology
Most of the evidence for using rituximab in adults with MCD and FSGS comes from uncontrolled and non-r andomised observational studies performed outside the UK with small sample sizes. The populations in the included studies varied, as did the dose of rituximab used, adjuvant treatment, and follow-up time. The studies in people with MCD and FSGS in their native kidney ys reported that treatment with rituximab reduced disease relapse rates, or achieved complete or partial remission. The study in renal transplant recipients with MCD and FSGS did not report any significant difference in treatment outcomes for those treated with rituximab compared to those receiving other immunosuppressants
Minimal change disease and focal segmentalMinimal change disease and focal segmental
glomerulosclerosis in adults: rituximabglomerulosclerosis in adults: rituximab
Evidence summary
Published: 4 November 2016
nice.org.uk/guidance/es1
Ochi A, Takei T, Nakayama K, et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern Med 2012; 51:759.